WVU Medicine Introduces Osseointegrated Prosthesis Technology

WVU Medicine is one of the first medical centers in the country to offer the Integrum Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA™) Implant System for the treatment of lower extremity amputations.

“Being one of the select facilities in the country to offer a multidisciplinary amputation clinic that incorporates this groundbreaking technology of osseointegration places our group at the forefront of amputee care,” Brock Lindsey, M.D., WVU Medicine orthopedic surgeon and Musculoskeletal Oncology and Adult Reconstruction director, said.

Osseointegration is a surgical procedure in which the prosthesis is integrated and permanently implanted into the bone. The revolutionary approach and viable alternative to a standard socket prosthesis offers a range of benefits for amputee patients, including improved mobility, enhanced comfort, reduced pressure, and stable attachment.

The OPRA™ Implant System is installed via two surgical procedures. In the first surgery, the fixture is implanted into the bone, which requires about six months of healing time for the bone to fully grow onto the fixture and anchor it. In the second surgery, an abutment is attached to the fixture and extends through the skin to connect to the external prosthesis. Another six months of rehabilitation is required, including fitting with a customized final prosthesis.

“We have already seen an increase in function and ease of use in our patients who have had the procedure,” Dr. Lindsey said.

The OPRA™ Implant System is the first and only FDA-approved technology for bone-anchored prostheses in the United States. In December 2020, the FDA approved OPRA for individuals who have transfemoral, or above-knee, amputations and those who have or are anticipated to have rehabilitation problems with, or cannot use, a conventional socket prosthesis.

For an appointment in the amputation clinic, call 304-598-4830. For more information on WVU Medicine Orthopedics, visit WVUMedicine.org/Ortho.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version